Uncategorized
Ozurdex given at same time as PPV may help stabilize retinal conditions
A sustained-release dexamethasone device implanted during pars plana vitrectomy may be effective in pre-emptively reducing macular edema in patients with various underlying ocular diseases at risk for inflammation.Researchers retrospectively reviewed the safety and effectiveness of Ozurdex (dexamethasone intravitreal implant 0.7 mg, Allergan) implantation in 15 eyes undergoing pars plana vitrectomy for indications including uveitis, age-related macular degeneration, central retinal vein occlusion, diabetic macular edema, hemiretinal vein occlusion, proliferative vitreoretinopathy, retinal detachment and subconjunctival hemorrhage. Lens status varied, with patients being phakic, pseudophakic or aphakic.